论文部分内容阅读
Atrix Laboratories的3月长效制剂促黄体(生成)激素释放激素（LHRH）促进剂亮氨酰脯氨酸（leur-prolide ，Leuprogel）的Ⅲ期临床试验结果显示：117例前列腺癌患者在用药3个月后，其睾酮水平呈显著下降。2001年3月，Atrix向美国FDA递交了用于治疗晚期前列腺癌的一月1次Leuproge
Atrix Laboratories March long-acting preparation luteinizing hormone (LHRH) promoter leucine proline (leur-prolide, Leuprogel phase III clinical trial results show that: 117 cases of prostate cancer patients in the medication 3 After a few months, its testosterone level decreased significantly. March 2001, Atrix to the United States FDA submitted for the treatment of advanced prostate cancer January 1 Leuproge